VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.14%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$204M
AUM Growth
+$15.9M
(+8.5%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
8.1%
Top 10 Holdings %
Top 10 Hldgs %
6.14%
Holding
488
New
66
Increased
245
Reduced
135
Closed
40
Top Buys
| 1 |
CrowdStrike
CRWD
|
$1.1M |
| 2 |
Netflix
NFLX
|
$1.03M |
| 3 |
Qualcomm
QCOM
|
$1.03M |
| 4 |
Royal Caribbean
RCL
|
$1M |
| 5 |
TJX Companies
TJX
|
$973K |
Top Sells
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.11M |
| 2 |
Eli Lilly
LLY
|
$937K |
| 3 |
Freeport-McMoran
FCX
|
$933K |
| 4 |
Align Technology
ALGN
|
$933K |
| 5 |
Martin Marietta Materials
MLM
|
$930K |
Sector Composition
| 1 | Financials | 26.66% |
| 2 | Healthcare | 19.14% |
| 3 | Technology | 17.16% |
| 4 | Energy | 7.21% |
| 5 | Industrials | 6.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
ADMA Biologics
ADMA
$4.03B
| $342K | 0.17% |
30,552
-63,760
| -68% | -$713K |
|
202
Ligand Pharmaceuticals
LGND
$3.25B
| $341K | 0.17% |
4,049
-1,579
| -28% | -$133K |
|
203
Exelixis
EXEL
$10.2B
| $337K | 0.17% |
14,998
-1,348
| -8% | -$30.3K |
|
204
Legend Biotech
LEGN
$6.66B
| $334K | 0.16% |
7,542
+1,335
| +22% | +$59.1K |
|
205
Harmony Biosciences
HRMY
$2.07B
| $334K | 0.16% |
11,067
-213
| -2% | -$6.43K |
|
|
BPMC
206
DELISTED
Blueprint Medicines
BPMC
| $334K | 0.16% |
3,096
-1,450
| -32% | -$156K |
|
207
Madrigal Pharmaceuticals
MDGL
$9.65B
| $333K | 0.16% |
1,189
+821
| +223% | +$230K |
|
208
Neurocrine Biosciences
NBIX
$14.3B
| $333K | 0.16% |
2,417
-723
| -23% | -$99.5K |
|
209
Krystal Biotech
KRYS
$4.35B
| $331K | 0.16% |
1,802
+1,058
| +142% | +$194K |
|
210
Y-mAbs Therapeutics
YMAB
$390M
| $330K | 0.16% |
+27,332
| New | +$330K |
|
|
ITCI
211
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $330K | 0.16% |
4,814
-1,019
| -17% | -$69.8K |
|
212
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $328K | 0.16% |
17,556
-4,791
| -21% | -$89.4K |
|
213
BioCryst Pharmaceuticals
BCRX
$1.74B
| $327K | 0.16% |
52,865
-6,392
| -11% | -$39.5K |
|
214
Biogen
BIIB
$20.6B
| $326K | 0.16% |
1,408
-78
| -5% | -$18.1K |
|
215
Theravance Biopharma
TBPH
$703M
| $326K | 0.16% |
38,386
+3,779
| +11% | +$32K |
|
216
Roivant Sciences
ROIV
$8.82B
| $322K | 0.16% |
30,467
-3,766
| -11% | -$39.8K |
|
217
BioMarin Pharmaceuticals
BMRN
$11.1B
| $322K | 0.16% |
3,910
+6
| +0.2% | +$494 |
|
218
Incyte
INCY
$16.9B
| $318K | 0.16% |
5,254
-715
| -12% | -$43.3K |
|
|
SWTX
219
DELISTED
SpringWorks Therapeutics
SWTX
| $317K | 0.16% |
8,415
-2,572
| -23% | -$96.9K |
|
220
Ultragenyx Pharmaceutical
RARE
$3.07B
| $314K | 0.15% |
7,638
-661
| -8% | -$27.2K |
|
221
Iovance Biotherapeutics
IOVA
$901M
| $313K | 0.15% |
39,069
+27,832
| +248% | +$223K |
|
|
SAGE
222
DELISTED
Sage Therapeutics
SAGE
| $311K | 0.15% |
28,639
+10,674
| +59% | +$116K |
|
223
Phathom Pharmaceuticals
PHAT
$875M
| $310K | 0.15% |
30,078
+20,377
| +210% | +$210K |
|
224
Dynavax Technologies
DVAX
$1.18B
| $308K | 0.15% |
27,423
+21,041
| +330% | +$236K |
|
225
Amicus Therapeutics
FOLD
$2.46B
| $307K | 0.15% |
30,939
+335
| +1% | +$3.32K |
|